Bolden Therapeutics
PrivateLast Round
Grant
Aug 2, 2024
Total Funding Raised
$3.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Bolden Therapeutics operates in Healthcare & Life Sciences and is based in Providence, Rhode Island. Its latest recorded funding round was a Grant round in August 2024.
Bolden Therapeutics is a biotechnology company that develops first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system illnesses such as Alzheimer's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bolden Therapeutics Comparables
Compare Bolden Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Leal Therapeutics | 82% | |
| Myrobalan Therapeutics | 77% | |
| Ionis Pharmaceuticals, Inc. | 70% |
For institutional investors. Book with your work email.
Bolden Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 2, 2024 | ||||
| Pre Seed | Jan 17, 2024 | ||||
| Grant | Sep 16, 2022 | ||||
| Grant | Jun 29, 2022 | ||||
| Grant | Sep 27, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Bolden Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Resolute Venture Partners | Pre Seed |
| NIH RADx | Grant |
| National Institute on Aging | Grant |
| Resolute Ventures | Pre Seed |
| LifeSpan Vision Ventures | Pre Seed |
| National Institutes of Health (NIH) | Grant |
| Slater Technology Fund | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 183% MoM.
- May 18, 2026
Monthly visitors increased 135% MoM, reaching 836.
For institutional investors. Book with your work email.
Bolden Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Bolden Therapeutics's valuation, stock price, and market status.
Is Bolden Therapeutics a public or private company?
Bolden Therapeutics is a private company.
What is the current stock price of Bolden Therapeutics?
Bolden Therapeutics is a private company, so its shares have no public market price. Caplight tracks Bolden Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bolden Therapeutics worth (valuation)?
Valuation information for Bolden Therapeutics is not publicly available.
Can I buy Bolden Therapeutics stock?
Bolden Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bolden Therapeutics's last funding round?
Bolden Therapeutics's most recent funding round was Grant on August 2, 2024.
Who are the main investors in Bolden Therapeutics?
Key investors in Bolden Therapeutics include Resolute Venture Partners, Resolute Ventures.
Will Bolden Therapeutics IPO soon?
No public IPO plans have been announced for Bolden Therapeutics.
How can I track Bolden Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Bolden Therapeutics's shares on secondary markets.